|
WO2021072372A1
|
|
Variant igf2 constructs
|
|
WO2021046443A1
|
|
Method for capturing and purification of biologics
|
|
WO2021026447A1
|
|
Methods of treating fabry disease in patients having a mutation in the gla gene
|
|
WO2020252129A1
|
|
Methods of treating fabry disease in patients having renal impairment
|
|
WO2020163480A1
|
|
Recombinant human acid alpha-glucosidase and uses thereof
|
|
TW202042812A
|
|
Methods of reducing cerebrovascular events in patients with fabry disease
|
|
US2020147241A1
|
|
Disulfide bond stabilized polypeptide compositions and methods of use
|
|
CA3098674A1
|
|
Gene therapy constructs and methods of use
|
|
AU2019217868A1
|
|
Use of migalastat for treating fabry disease in pregnant patients
|
|
CN112203657A
|
|
Treatment of patients with classic Fabry disease
|
|
SG11202101117QA
|
|
Methods of treating fabry disease in patients having a mutation in the gla gene
|
|
CA3083951A1
|
|
Cdkl5 expression variants and cdkl5 fusion proteins
|
|
CA3074450A1
|
|
Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
|
|
AU2018220047A1
|
|
A method for treatment of fabry disease
|
|
EP3630114A1
|
|
Methods of treating fabry patients having renal impairment
|
|
MX2019014410A
|
|
Methods of treating fabry patients having renal impairment.
|
|
CA3063615A1
|
|
Recombinant human acid alpha-glucosidase
|
|
AU2018258348A1
|
|
Novel compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders
|
|
EP3568152A1
|
|
Recombinant alpha-galactosidase a for treatment of fabry disease
|
|
TW201907921A
|
|
Treatment of fabry disease in ert-naive and ert-experienced patients
|
